Stock Analiz

Agenus Inc. AGEN

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2000 · data as of November 13, 2026

$6.73Market cap $305M
Open the interactive analysis →

Agenus Inc. (AGEN) is a healthcare company listed in the US with a market value of about $305M. In the twelve months to September 30, 2026 it had revenue of $134M and net income of $31M, a net margin of 23.0%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a P/E of 29.3, 5-year revenue growth of 5% a year, a 5-year average ROIC of -402%.

About Agenus

Agenus is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2000. Revenue went from $7M in 2014 to $114M in 2025, growth of about 28.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 111% over three years (dilution for shareholders). It spends 69% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)29.3
Forward P/E—
P/FCF—
P/S2.3
P/B—
EV/EBITDA4.7
PEG—
Dividend yield0.00%
FCF yield-34.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)10.4%
Revenue growth (5 yrs, per year)5.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-122.0%
ROIC (5-yr avg.)-402.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$134M$114M$103M$156M$98M$296M$88M$150M$37M$43M$23M
Net income$31M-$101000-$227M-$246M-$220M-$24M-$181M-$108M-$162M-$121M-$127M
Free cash flow-$104M-$77M-$159M-$234M-$228M-$24M-$143M-$23M-$135M-$97M-$92M
EPS (diluted)$0.23$0.00$-10.59$-13.75$-15.64$-0.00$-0.02$-0.02$-0.03$-0.02$-29.20
Net margin23.0%-0.1%-219.8%-157.4%-224.7%-8.2%-205.4%-71.9%-440.5%-281.5%-562.6%
ROIC————-826.5%21.9%———-119.0%-117.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $27.00, 301% above the current price; targets range from $16.00 to $40.00; the consensus rating is “Strong buy”; expected EPS is $0.82 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Agenus’s P/E ratio?

About 29.3, based on the last twelve months of diluted earnings per share.

Does Agenus pay a dividend?

Not currently.

Is Agenus a good stock to buy?

We do not give buy or sell advice. Agenus scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.